Biotech: Page 50
-
Jonathan Gardner/BioPharma Dive
Roche’s hemophilia gene therapy holds steady with longer-term data
Roche’s subsidiary Spark has offered few updates on its hemophilia A treatment since being acquired in 2019. New data at ASH show the therapy can maintain levels of a key blood-clotting protein for years.
By Jonathan Gardner • Dec. 12, 2022 -
Brian Tucker/BioPharma Dive
Clovis files for bankruptcy
Perhaps best known for its marketed PARP inhibitor Rubraca, the cancer drugmaker is now in the process of reorganizing its debt and selling off assets.
By Jacob Bell • Dec. 12, 2022 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Adeline Kon/BioPharma Dive
Sponsored by Allucent[Podcast] Thinking Big for Small and Mid-Sized Biotechs
This podcast series explores how to help small and mid-sized companies get innovative treatments to the people who need them.to help small and mid-sized companies get innovative treatments to the people who need them.
By BioPharma Dive's studioID • Updated Dec. 15, 2022 -
Retrieved from Istock.
Sponsored by VeradigmBiopharma trends leaders should consider for 2023
What healthcare trends biopharma leaders should pay attention to in 2023 and how to set yourself up for success.
By Tom Langan, President and Chief Commercial Officer, Veradigm • Dec. 12, 2022 -
gorodenkoff via Getty Images
Biotech layoffs claim more jobs at Sensei, Instil, TherapeuticsMD
Cell therapy Instil Bio will cut 60% of its staff and Sensei Bio will reduce its headcount by 40%. TherapeuticsMD, meanwhile, is laying off all its employees days after announcing a deal to sell off its drug portfolio.
By Delilah Alvarado • Dec. 9, 2022 -
Permission granted by Westlake Village BioPartners
Dantari emerges with a new way to make cancer drug conjugates
As the success of drugs like Enhertu catalyzes new investment in antibody-drug conjugates, the California startup is launching with plans to develop more potent versions of the targeted cancer medicines.
By Gwendolyn Wu • Dec. 8, 2022 -
Courtesy of Apogee Therapeutics
Immune drug developer Apogee emerges as first spinout of biotech Paragon
The new biotech launches with $169 million in venture funding and plans to advance its first drug into clinical testing next year.
By Delilah Alvarado • Dec. 7, 2022 -
Sarah Silbiger via Getty Images
MEI, Kyowa stop lymphoma drug trials after FDA meeting
The decision not to run a Phase 3 trial is the latest fallout from U.S. regulators’ recent moves to closely evaluate a class of drugs called PI3 kinase inhibitors.
By Jonathan Gardner • Dec. 6, 2022 -
Permission granted by Steve Paul.
Karuna switches CEOs ahead of FDA filing for schizophrenia drug
Former Allergan commercial executive Bill Meury will take over for longtime CEO Steve Paul as the company prepares to seek U.S. approval of the treatment, known as KarXT, next year.
By Christopher Newman • Dec. 6, 2022 -
Wirestock via Getty Images
Star Therapeutics launches Vega, growing its galaxy of drug startups
The second startup to emerge from Star’s “hub-and-spoke” model aims to develop a Hemlibra-like antibody drug for the blood clotting disorder von Willebrand disease.
By Gwendolyn Wu • Dec. 6, 2022 -
Permission granted by Entact Bio
With $81M, Entact Bio takes a new approach to fixing helpful proteins
Entact Bio aims to develop medicines that can enhance helpful proteins, rather than block harmful ones, a twist on the usual drugmaking playbook.
By Gwendolyn Wu • Dec. 6, 2022 -
Permission granted by Sage Therapeutics
Q&A // Emerging biotechBiotech veteran Jeff Jonas on leaving Sage, guiding new biotechs and his ‘personal odyssey’
In an interview with BioPharma Dive, the longtime industry executive discussed becoming a biotech investor and his plans for Abio-X, a new incubator with $150 million to spend on startups.
By Ben Fidler • Dec. 6, 2022 -
monsitj via Getty Images
TherapeuticsMD to offload drugs to Australia’s Mayne after failed buyout
After a private equity takeover unraveled this summer, the women’s health company is selling its drug portfolio to Mayne Pharma in a $153 million deal.
By Delilah Alvarado • Dec. 5, 2022 -
Permission granted by Regis University
Sponsored by Regis UniversityHow a government biologist with the USDA built her community — and her career — at Regis University
When Talisa Puentes-Ortega got the chance to advance her career by going back to school, Regis provided more than an environmental biology degree — it was the foundation of a community that continues to support her.
Dec. 5, 2022 -
Leonid Sorokin via Getty Images
SQZ CEO steps down as company restructures, cuts jobs
The biotech will lay off 60% of its staff and reprioritize its research to focus on a "second-generation" approach to the cell therapies it’s been developing.
By Ned Pagliarulo • Dec. 1, 2022 -
gorodenkoff via Getty Images
Sana reshuffles drug pipeline, becoming latest biotech to cut staff
The richly funded drugmaker will cut 15% of its workforce, or about 75 employees, as well as stop work on one of its preclinical research programs.
By Delilah Alvarado • Nov. 30, 2022 -
Permission granted by Bluebird bio
Bluebird sells regulatory fast pass to Argenx for $102M
The priority review voucher is one of two that Bluebird received for winning FDA approvals of its gene therapies Zynteglo and Skysona, and its sale gives the company needed cash.
By Christopher Newman • Nov. 30, 2022 -
iStock / Getty Images Plus via Getty Images
Gene editing startup iECURE returns to investors for fresh funding
The company, which draws on research by Jim Wilson’s lab at UPenn, says the $65 million it raised will support the start of human testing of its lead drug through to initial clinical data.
By Gwendolyn Wu • Nov. 30, 2022 -
skynesher via Getty Images
State of Play: A closer look at hotspots of emerging biotech research
Our story on targeted protein degraders is the latest in a series examining new areas of biotech investment, like sodium channel blockers and RNA editing.
By BioPharma Dive staff • Nov. 29, 2022 -
smartboy10 via Getty Images
State of PlayBiomolecular condensates: tiny droplets with big potential
Research into the cellular droplets has spawned at least five companies in recent years. But the closure of one of them, Faze Medicines, shows the significant obstacles they still face.
By Ben Fidler • Nov. 29, 2022 -
nortonrsx via Getty Images
CinCor shares dive after blood pressure drug fails key trial
The company, one of several testing a drug for resistant hypertension, had previously pulled off one of the top performing biotech IPOs this year.
By Gwendolyn Wu • Nov. 28, 2022 -
Sarah Silbiger via Getty Images
Spectrum to lay off R&D staff after FDA drug rejection
The company will cut its R&D workforce by 75% and discontinue development of its experimental lung cancer drug poziotinib.
By Delilah Alvarado • Nov. 28, 2022 -
Courtesy of Sarepta
FDA grants speedy review to Sarepta’s Duchenne gene therapy
The agency will decide on an accelerated approval of Sarepta’s treatment by May 29, months before results are expected from a potentially confirmatory Phase 3 trial.
By Jonathan Gardner • Nov. 28, 2022 -
Michael Santiago/Getty Images via Getty Images
Biotech ObsEva sells drug rights to forestall funding crunch
In an effort to extend its cash runway and keep its stock listing, ObsEva is offloading rights to an experimental preterm labor drug in a deal with Xoma.
By Delilah Alvarado • Nov. 22, 2022 -
Photo illustration: Shaun Lucas and Karissa Waddick/Industry Dive; Getty Images
The next era of Greater Boston’s biotech boom
Over the past two decades, the Cambridge area has become a nerve center for biotech in the U.S. But to stay relevant and accessible, the hub is expanding to the suburbs.
By Karissa Waddick , Shaun Lucas , Julia Himmel • Nov. 22, 2022
Previous
